BioVectra and Quanta BioDesign Announce Cooperation

Share Article

BioVectra, a specialized cGMP manufacturer of API’s and bioprocessing materials, announce their appointment by Quanta BioDesign to represent Quanta. The new 3-year agreement names BioVectra as Quanta’s agent for their discrete MPEG reagents in Europe and North America.

BioVectra, a specialized cGMP manufacturer of API’s and bioprocessing materials, announce their appointment by Quanta BioDesign to represent Quanta. The new 3-year agreement names BioVectra as Quanta’s agent for their discrete MPEG reagents in Europe and North America.

BioVectra will provide their customers access to Quanta BioDesign’s complete range of unique product and service offerings. This strategic partnership also complements BioVectra`s own strengths in MPEG offerings, including custom products.

Utilizing BioVectra as a strategic supplier for the North American and European markets provides Quanta with an extensive and experienced business development and sales team, as well as an extensive supply chain network.

In addition to providing bioprocessing reagents, BioVectra offers cGMP custom manufacturing of MPEG reagents and both biologic and synthetic API’s, from fermentation, synthesis and natural product extraction. This cGMP experience makes BioVectra a unique agent, able to leverage its operations and quality assurance understanding to meet the exact individual needs of biologic drug manufacturers.

About Quanta BioDesign
Quanta BioDesign, located in Powell, Ohio, develops and commercializes an extensive line of products for companies involved in drug discovery and diagnostic development programs based on a proprietary discrete polyethylene glycol (dPEG®) chemistry.

Quanta’s single molecular weight ethylene glycol conjugation technology, dPEG®, can eliminate common problems found in the development of diagnostic and therapeutic products, such as aggregation and nonspecific interactions, poor water solubility, poor delivery, delivery issues/options, short serum half-life, toxicity and antigenicity.

The dPEG® product line is a unique technology platform which can be custom tailored to meet specific physical, chemical and morphological requirements in a broad array of diagnostic and therapeutic applications.

For further information contact:
Heather Delage - Director, Sales & Marketing
Tel: 902-566-9116, ext. 6236
hdelage(at)biovectra(dot)com
http://www.biovectra.com

Website: http://www.quantabiodesign.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lee DesRosiers

514-246-5266
Email >
Visit website